Incyte Corp. (INCY) reported a strong third quarter, with $1.3 billion in total net sales, representing 14% growth year-over-year. The next major catalyst for INCY will be the American Society of Hematology meeting that runs Dec. 12-15, advises John McCamant, editor of Medical Technology Stock Letter.

Notably, management highlighted 25% pro forma US sales growth for Opzelura after adjusting GtN benefit, reflecting strong underlying demand. INCY raised 2026 total net sales guidance to $5,210-5,300 million (versus the prior $5,130-5,260 million range), driven by higher Opzelura and hematology/oncology sales forecasts.

Incyte Corp. (INCY)

chart

INCY will provide an mCALR update in 1L MF at ASH with data from 55 1L MF patients including around 20 patients with ‘989+rux combination. At EHA, ‘989 demonstrated 47% SVR35 in JAKi-ineligible patients (60% in type 1 patients) which might serve as a relevant benchmark for frontline MF patients.

At the December meeting, we’re looking for key clinical data and strategy updates for the mCALR program in 1L myelofibrosis, representing the other critical component of the broader Jakafi revenue replacement strategy, alongside business development.

Subscribe to Medical Technology Stock Letter here...